View Older Stories View More Recent Stories

May 9, 2024 04:05PM Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 7, 2024 08:30AM Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Apr 30, 2024 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Apr 26, 2024 08:00AM FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
Apr 8, 2024 04:05PM Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
Mar 28, 2024 08:31AM FDA Expands Indication for Gilead's (GILD) Vemlidy to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
Mar 28, 2024 08:30AM FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
Mar 28, 2024 07:02AM Gilead Sciences (GILD) and Xilio (XLO) Enter Exclusive License Agreement for Tumor-Activated IL-12 Program
Mar 28, 2024 07:00AM Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Mar 22, 2024 09:18AM Gilead Sciences (GILD) Announces Completion of Acquisition of CymaBay (CBAY)
Mar 22, 2024 09:18AM Gilead Sciences Announces Completion of Acquisition of CymaBay
Mar 11, 2024 08:24AM Gilead Sciences (GILD) Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay (CBAY) Tender Offer
Mar 11, 2024 08:24AM Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
Mar 6, 2024 10:25AM Gilead Sciences (GILD) and Merck (MRK) Report Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Mar 6, 2024 10:25AM Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Mar 6, 2024 08:01AM Gilead Sciences (GILD), Merus (MRUS) Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
Mar 6, 2024 08:00AM Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
Mar 5, 2024 04:35PM Gilead Sciences (GILD) Reports New Real-World Data Supporting the Use of Veklury for People Hospitalized With COVID-19
Mar 5, 2024 04:35PM New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
Mar 5, 2024 04:31PM Gilead Sciences (GILD) HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
Mar 5, 2024 04:30PM Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
Mar 5, 2024 07:03AM RedHill Biopharma's (RDHL) Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
Mar 5, 2024 07:00AM RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
Feb 28, 2024 05:15PM Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
Feb 27, 2024 10:00AM Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
Feb 26, 2024 04:07PM Gilead Sciences (GILD) Announces FDA Approval of Expanded Indication for Biktarvy
Feb 26, 2024 04:05PM U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
Feb 26, 2024 08:33AM Gilead Sciences (GILD) to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
Feb 26, 2024 08:30AM Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
Feb 20, 2024 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Feb 20, 2024 09:25AM Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
Feb 20, 2024 07:00AM RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
Feb 12, 2024 08:32AM Gilead Sciences (GILD) to Acquire CymaBay Therapeutics (CBAY) for $32.50 Per Share, $4.3 Billion
Feb 12, 2024 08:30AM Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Feb 9, 2024 11:00AM Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
Jan 29, 2024 05:01PM Gilead Sciences (GILD), Arcus (RCUS) Announce Amended Collaboration and $320M Equity Investment
Jan 29, 2024 05:00PM Gilead and Arcus Announce Amended Collaboration and Equity Investment
Jan 23, 2024 04:05PM Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024
Jan 3, 2024 11:15AM Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
Dec 21, 2023 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
Dec 20, 2023 08:45AM RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Dec 19, 2023 07:01AM Gilead Sciences (GILD) and Compugen (CGEN) Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Dec 19, 2023 07:00AM Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Dec 11, 2023 12:00PM Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
Nov 15, 2023 06:00AM Kite (GILD) and Arcellx (ACLX) Expand Strategic Partnership
Nov 15, 2023 06:00AM Kite and Arcellx Announce Expansion in Strategic Partnership
Nov 15, 2023 06:00AM ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
Nov 14, 2023 08:45AM Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
Nov 8, 2023 07:13PM Gilead Sciences to Present at Upcoming Investor Conferences
Nov 3, 2023 11:00AM Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
View More Recent Stories View Older Stories